Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tag-7 gene-modified tumor cell vaccine in melanoma and renal cell cancer
NCT04180774Phase 2Completed
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Jan 2001
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TAG-7 gene-modified tumor cells-based vaccine in melanoma, renal cell carcinoma (RCC), sponsored by N.N. Petrov National Medical Research Center of Oncology. Started Jan 2001; status: completed.
02
Drugs
TAG-7 gene-modified tumor cells-based vaccine
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04180774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180774.